Valiant Laboratories Ltd
Incorporated in 1980, Valiant Laboratories
Ltd manufactures and deals in Pharmaceuticals and speciality chemicals[1]
- Market Cap ₹ 454 Cr.
- Current Price ₹ 105
- High / Low ₹ 158 / 75.2
- Stock P/E
- Book Value ₹ 53.9
- Dividend Yield 0.00 %
- ROCE -0.43 %
- ROE -0.91 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of 4.89% over last 3 years.
- Company has high debtors of 197 days.
- Working capital days have increased from 133 days to 195 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
182 | 292 | 334 | 182 | 133 | |
132 | 249 | 299 | 190 | 138 | |
Operating Profit | 50 | 42 | 35 | -8 | -5 |
OPM % | 27% | 15% | 11% | -5% | -4% |
1 | 2 | 5 | 10 | 5 | |
Interest | 2 | 0 | 0 | 0 | 0 |
Depreciation | 3 | 2 | 2 | 2 | 2 |
Profit before tax | 47 | 42 | 38 | -1 | -1 |
Tax % | 35% | 34% | 24% | -145% | 49% |
31 | 28 | 29 | 0 | -2 | |
EPS in Rs | 16.89 | 8.91 | 0.08 | -0.49 | |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -23% |
TTM: | -27% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 25% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | -30% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 5% |
Last Year: | -1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Equity Capital | 10 | 16 | 33 | 43 | 43 |
Reserves | 78 | 55 | 68 | 193 | 191 |
1 | 61 | 60 | 60 | 60 | |
17 | 49 | 52 | 28 | 23 | |
Total Liabilities | 106 | 182 | 213 | 325 | 317 |
20 | 22 | 30 | 32 | 30 | |
CWIP | 0 | 1 | 0 | 0 | 0 |
Investments | 0 | 0 | 34 | 119 | 165 |
87 | 158 | 149 | 174 | 122 | |
Total Assets | 106 | 182 | 213 | 325 | 317 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
9 | 2 | 23 | 49 | -22 | |
-17 | -12 | -21 | -183 | 25 | |
11 | 6 | -2 | 136 | -0 | |
Net Cash Flow | 4 | -4 | 0 | 2 | 3 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Debtor Days | 85 | 139 | 97 | 92 | 197 |
Inventory Days | 18 | 25 | 17 | 22 | 12 |
Days Payable | 37 | 72 | 62 | 54 | 61 |
Cash Conversion Cycle | 66 | 91 | 52 | 60 | 149 |
Working Capital Days | 103 | 111 | 106 | 98 | 195 |
ROCE % | 38% | 26% | -2% | -0% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16h - Newspaper Publication of the Financial Results for the quarter and year ended March 31, 2025.
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
2d - Approved FY25 audited results; re-appointed auditors; company secretary resigned; audit and risk committees reconstituted.
-
Financial Results For The Quarter And Year Ended March 31, 2025
2d - Audited FY25 results: standalone profit Rs.215L, consolidated loss Rs.220L; auditor re-appointments; company secretary resignation.
-
Board Meeting Outcome for Outcome Of The Board Meeting Dated May 20, 2025.
2d - Approved FY25 audited results; standalone profit Rs.215L, consolidated loss Rs.220L; auditor re-appointments; company secretary resignation.
-
Board Meeting Intimation for Board Meeting Intimation For Considering And Approving Audited Standalone And Consolidated Financial Results For The Quarter And Year Ended March 31, 2025.
14 May - Board meeting on May 20 to approve FY25 audited results; trading window closed till May 22.
Business Overview:[1][2]
VLL is in the active pharmaceutical ingredient manufacturing business. It manufactures finished dosage forms of paracetamol API viz. Tablets, Capsules, and Other medications. Paracetamol API is a key ingredient used to treat a variety of conditions including Headache, Arthritis, Muscle Aches, Toothache, Backache, Cold, and Fever